



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Jessie Lai-Sim Au, PharmD, Ph.D.**

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: **April 22, 2022**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item:

On April 22, 2022, the committee will discuss supplemental new drug application (sNDA) 213176/S-002, for Ukoniq (umbralisib) tablets, and biologics license application (BLA) 761207, for ublituximab injection, both submitted by TG Therapeutics, Inc. The proposed indication (use) for these two products is in combination for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition, the committee will also discuss the existing umbralisib indications in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma under 21 CFR 314.500 (subpart H, accelerated approval regulations), I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/Investments	Health sector mutual fund holdings in (b) (6)	\$ (b) (6)
II. Other Imputed Interests		
Stocks/Investments for Institute of Quantitative Systems Pharmacology (IQSP), founding director and chair	Health sector mutual fund holdings in (b) (4), (b) (6)	\$ (b) (4), (b) (6)

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/
Signature

_____3/31/2022_____
Date